E2F1 rs3213150多态性影响了急性髓性白血病患者的细胞氨基酸敏感性和预后
Yanfeng Liu1,2,3, Peng Chen1,4, Ge Chen1,4
1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Annals of hematology
|September 4, 2023
概括
E2F1 rs3213150的多态性显著影响了细胞氨酸 (Ara-C) 化疗耐药性和急性髓性白血病 (AML) 的患者预后. 这种遗传变异会影响AML患者的治疗结果和生存率.
科学领域:
- 遗传学 是一个遗传学.
- 在瘤学瘤学.
- 药物基因组学 药物基因组学
背景情况:
- 赛塔拉宾 (Ara-C) 是急性髓性白血病 (AML) 的关键治疗方法,但患者的反应有很大差异.
- 之前的研究将E2F1 rs3213150多态与Ara-C缓解率联系起来,但潜在的机制仍然不清楚.
研究的目的:
- 确认E2F1 rs3213150多态和AML患者的Ara-C耐药性之间的关联.
- 研究这种多形态对患者预后的影响,阐明分子机制.
主要方法:
- 在922名AML患者中使用桑格测序对E2F1 rs3213150的基因定型.
- 基因型对化学敏感性和预后的影响通过物流和考克斯回归分析.
- 露西法酶记者基因测定和RNA测序以评估E2F1表达和基因表达差异.
主要成果:
- 与G等位基因携带者相比,具有AA基因型的患者表现出明显更高的Ara-C耐药性 (41.94%对27.94%,P=0.002).
- 亚亚基因型与较短的整体存活率 (529d与644d相比,P=0.008) 和无病存活率 (519d与556d相比,P=0.023) 相关.
- rs3213150 G>A突变导致E2F1表达的减少.
结论:
- E2F1 rs3213150多态性是影响中国急性髓性白血病 (AML) 患者的cytarabine (Ara-C) 化学敏感性和预后的重要因素.
- 这种遗传标志物为了解Ara-C耐药机制和预测治疗结果提供了有价值的信息.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:31Translation
142.2K
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
142.2K